Estrella Immunopharma
ESLA
13 hedge funds and large institutions have $19.7M invested in Estrella Immunopharma in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 14 closing their positions.
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
25.76% less ownership
Funds ownership: 58.58% → 32.82% (-26%)
43% less capital invested
Capital invested by funds: $34.5M → $19.7M (-$14.8M)
43% less funds holding
Funds holding: 23 → 13 (-10)
71% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCAM
Owl Creek Asset Management
New York
|
+$2.59M |
| 2 |
SIA
SkyView Investment Advisors
Shrewsbury,
New Jersey
|
+$1.27M |
| 3 |
MC
Meteora Capital
Boca Raton,
Florida
|
+$315K |
| 4 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$278K |
| 5 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ASM
ATW SPAC Management
New York
|
-$3.92M |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$3.92M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$2.03M |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.77M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.76M |
ESLA Hedge Fund Activity: Q4 2022 in Review
13 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q4 2022, worth a combined $19.7M — down 43% from $34.5M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ESLA and 4 opened new positions — a net loss of 10 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Owl Creek Asset Management, opening a new position worth an estimated $2.59M. The largest seller was ATW SPAC Management, exiting entirely with an estimated $3.92M sold.
- 13 institutional investors held Estrella Immunopharma (ESLA) as of Q4 2022, down from 23 in Q3 2022.
- Funds reported $19.7M of Estrella Immunopharma stock for Q4 2022, down 43% quarter-over-quarter.
- 4 funds opened new Estrella Immunopharma positions in Q4 2022 and 14 closed out, a net change of -10 holders.
- The largest Estrella Immunopharma buyer in Q4 2022 was Owl Creek Asset Management, an estimated $2.59M added.
- The largest Estrella Immunopharma seller in Q4 2022 was ATW SPAC Management, an estimated $3.92M sold.
Based on aggregated 13F filings for Q4 2022.